Salim Syed
Stock Analyst at Mizuho Securities
(3.41)
# 2,356
Out of 5,004 analysts
1120
Total ratings
45%
Success rate
2.6%
Average return
Main Sectors:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASMB Assembly Biosciences | Reiterated: Buy | $45 → $53 | $23.67 | +123.91% | 41 | Aug 31, 2026 | |
| ATRA Atara Biotherapeutics | Reiterated: Buy | $18 | $8.81 | +104.31% | 82 | Aug 31, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $96 → $110 | $65.57 | +67.76% | 108 | Aug 31, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $170 | $150.93 | +12.64% | 112 | Aug 31, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $25 | $10.76 | +132.34% | 10 | Aug 31, 2026 | |
| AMGN Amgen | Reiterated: Hold | $303 → $352 | $414.61 | -15.10% | 172 | Aug 17, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | $62 → $73 | $44.75 | +63.13% | 18 | Aug 17, 2026 | |
| IOVA Iovance Biotherapeutics | Reiterated: Buy | $10 → $11 | $11.00 | - | 6 | Aug 17, 2026 | |
| IPSC Century Therapeutics | Reiterated: Buy | $8 | $1.67 | +379.04% | 4 | Aug 17, 2026 | |
| NKTX Nkarta | Reiterated: Buy | $12 | $2.75 | +336.36% | 43 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $47 | $24.97 | +88.23% | 6 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $221 → $241 | $227.60 | +5.89% | 133 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $121 → $137 | $123.89 | +10.58% | 8 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $23 | $3.78 | +508.47% | 81 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 → $118 | $64.66 | +82.49% | 146 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $97 | $26.05 | +272.36% | 4 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $163 | $56.21 | +189.98% | 24 | Jun 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.86 | +439.08% | 6 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $43 | $18.20 | +136.26% | 8 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.35 | +240.43% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $85 | $54.23 | n/a | 23 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $148.78 | n/a | 2 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $23.80 | n/a | 2 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $53 | $28.67 | n/a | 1 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $5.03 | n/a | 1 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.13 | n/a | 73 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $10.65 | n/a | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $60.26 | n/a | 1 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $22.84 | n/a | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.1 | $8.58 | n/a | 1 | Jul 2, 2019 |
Assembly Biosciences
Aug 31, 2026
Reiterated: Buy
Price Target: $45 → $53
Current: $23.67
Upside: +123.91%
Atara Biotherapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $18
Current: $8.81
Upside: +104.31%
BridgeBio Pharma
Aug 31, 2026
Reiterated: Buy
Price Target: $96 → $110
Current: $65.57
Upside: +67.76%
Gilead Sciences
Aug 31, 2026
Reiterated: Buy
Price Target: $170
Current: $150.93
Upside: +12.64%
Kura Oncology
Aug 31, 2026
Reiterated: Buy
Price Target: $25
Current: $10.76
Upside: +132.34%
Amgen
Aug 17, 2026
Reiterated: Hold
Price Target: $303 → $352
Current: $414.61
Upside: -15.10%
Enliven Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $62 → $73
Current: $44.75
Upside: +63.13%
Iovance Biotherapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $10 → $11
Current: $11.00
Upside: -
Century Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $8
Current: $1.67
Upside: +379.04%
Nkarta
Aug 17, 2026
Reiterated: Buy
Price Target: $12
Current: $2.75
Upside: +336.36%
Aug 5, 2026
Reiterated: Buy
Price Target: $47
Current: $24.97
Upside: +88.23%
Aug 3, 2026
Reiterated: Buy
Price Target: $221 → $241
Current: $227.60
Upside: +5.89%
Aug 3, 2026
Reiterated: Buy
Price Target: $121 → $137
Current: $123.89
Upside: +10.58%
Aug 3, 2026
Reiterated: Buy
Price Target: $27 → $23
Current: $3.78
Upside: +508.47%
Jun 23, 2026
Reiterated: Buy
Price Target: $100 → $118
Current: $64.66
Upside: +82.49%
Jun 23, 2026
Reiterated: Buy
Price Target: $97
Current: $26.05
Upside: +272.36%
Jun 18, 2026
Reiterated: Buy
Price Target: $163
Current: $56.21
Upside: +189.98%
Jun 10, 2026
Reiterated: Buy
Price Target: $10
Current: $1.86
Upside: +439.08%
Mar 30, 2026
Reiterated: Buy
Price Target: $45 → $43
Current: $18.20
Upside: +136.26%
Nov 14, 2025
Reiterated: Buy
Price Target: $8
Current: $2.35
Upside: +240.43%
May 20, 2025
Reiterated: Buy
Price Target: $85
Current: $54.23
Upside: n/a
Nov 22, 2024
Rated: Hold
Price Target: n/a
Current: $148.78
Upside: n/a
Nov 22, 2024
Rated: Hold
Price Target: n/a
Current: $23.80
Upside: n/a
May 28, 2024
Reiterated: Buy
Price Target: $53
Current: $28.67
Upside: n/a
Mar 25, 2024
Reiterated: Buy
Price Target: $25
Current: $5.03
Upside: n/a
Jun 16, 2023
Rated: Hold
Price Target: n/a
Current: $1.13
Upside: n/a
Mar 6, 2023
Reiterated: Buy
Price Target: $21
Current: $10.65
Upside: n/a
Nov 3, 2022
Reiterated: Buy
Price Target: $23
Current: $60.26
Upside: n/a
Aug 4, 2022
Reiterated: Buy
Price Target: $25
Current: $22.84
Upside: n/a
Jul 2, 2019
Reiterated: Buy
Price Target: $7.1
Current: $8.58
Upside: n/a